Provided by Tiger Fintech (Singapore) Pte. Ltd.

Insmed

98.73
+1.851.91%
Post-market: 98.26-0.5270-0.53%19:39 EDT
Volume:5.32M
Turnover:523.51M
Market Cap:17.98B
PE:-16.77
High:99.65
Open:96.46
Low:96.01
Close:96.88
Loading ...

Biotech stocks have been hit by 'DOGE' and other fears. Why they're a great value now.

Dow Jones
·
27 Mar

Is Insmed Incorporated (INSM) a Promising Biotech Stock According to Wall Street Analysts

Insider Monkey
·
26 Mar

Wells Fargo Sticks to Their Buy Rating for Insmed (INSM)

TIPRANKS
·
24 Mar

Insmed Is Maintained at Buy by B of A Securities

Dow Jones
·
20 Mar

Insmed Inc : Bofa Global Research Raises Price Objective to $96 From $92

THOMSON REUTERS
·
20 Mar

Insmed (INSM) Gets a Buy from Mizuho Securities

TIPRANKS
·
19 Mar

Is Insmed Incorporated (INSM) a Best Biotech Stock According to Billionaires?

Insider Monkey
·
18 Mar

Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

PR Newswire
·
10 Mar

Insmed’s Strategic Growth and Promising Pipeline Drive Buy Rating

TIPRANKS
·
07 Mar

Insmed Is Maintained at Buy by UBS

Dow Jones
·
07 Mar

UBS Adjusts Price Target on Insmed to $110 From $105, Maintains Buy Rating

MT Newswires Live
·
06 Mar

Insmed price target raised to $110 from $105 at UBS

TIPRANKS
·
06 Mar

Insmed to Benefit From Strong Launch of Brensocatib for Lung Disease, RBC Says

MT Newswires Live
·
26 Feb

Insmed Initiated at Outperform by RBC Capital

Dow Jones
·
26 Feb

Insmed Price Target Maintained With a $101.00/Share by Guggenheim

Dow Jones
·
25 Feb

RBC Capital Initiates Insmed at Outperform With $100 Price Target

MT Newswires Live
·
25 Feb

RBC Capital starts Insmed at Outperform on brensocatib launch momentum

TIPRANKS
·
25 Feb

Insmed initiated with an Outperform at RBC Capital

TIPRANKS
·
25 Feb

International Markets and Insmed (INSM): A Deep Dive for Investors

Zacks
·
24 Feb

Insmed: FDA won’t hold advisory meeting to discuss NDA for brensocatib

TIPRANKS
·
24 Feb